Xi-Fei Yang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6702605/publications.pdf

Version: 2024-02-01

43 papers	1,244 citations	471509 17 h-index	414414 32 g-index
48 all docs	48 docs citations	48 times ranked	1465 citing authors

#	Article	IF	Citations
1	Melatonin prevents neuroinflammation and relieves depression by attenuating autophagy impairment through FOXO3a regulation. Journal of Pineal Research, 2020, 69, e12667.	7.4	182
2	MAPT/Tau accumulation represses autophagy flux by disrupting IST1-regulated ESCRT-III complex formation: a vicious cycle in Alzheimer neurodegeneration. Autophagy, 2020, 16, 641-658.	9.1	117
3	Posterior basolateral amygdala to ventral hippocampal CA1 drives approach behaviour to exert an anxiolytic effect. Nature Communications, 2020, 11, 183.	12.8	82
4	Melatonin ameliorates cognitive deficits through improving mitophagy in a mouse model of Alzheimerâ€™s disease. Journal of Pineal Research, 2021, 71, e12774.	7.4	72
5	Electroacupuncture ameliorates beta-amyloid pathology and cognitive impairment in Alzheimer disease via a novel mechanism involving activation of TFEB (transcription factor EB). Autophagy, 2021, 17, 3833-3847.	9.1	64
6	Ultrasound with microbubbles improves memory, ameliorates pathology and modulates hippocampal proteomic changes in a triple transgenic mouse model of Alzheimer's disease. Theranostics, 2020, 10, 11794-11819.	10.0	55
7	Melatonin ameliorates Alzheimer-like pathological changes and spatial memory retention impairment induced by calyculin A. Journal of Psychopharmacology, 2011, 25, 1118-1125.	4.0	53
8	Ginsenoside Rg1 Ameliorates Behavioral Abnormalities and Modulates the Hippocampal Proteomic Change in Triple Transgenic Mice of Alzheimerâ€™s Disease. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-17.	4.0	47
9	Melatonin ameliorates anxiety and depressionâ€like behaviors and modulates proteomic changes in triple transgenic mice of Alzheimer's disease. BioFactors, 2017, 43, 593-611.	5.4	44
10	Low-dose oral copper treatment changes the hippocampal phosphoproteomic profile and perturbs mitochondrial function in a mouse model of Alzheimer's disease. Free Radical Biology and Medicine, 2019, 135, 144-156.	2.9	40
11	Identification of the Key Molecules Involved in Chronic Copper Exposure-Aggravated Memory Impairment in Transgenic Mice of Alzheimer's Disease Using Proteomic Analysis. Journal of Alzheimer's Disease, 2015, 44, 455-469.	2.6	33
12	Hippocampal Proteomic Alteration in Triple Transgenic Mouse Model of Alzheimerâ€™s Disease and Implication of PINK 1 Regulation in Donepezil Treatment. Journal of Proteome Research, 2019, 18, 1542-1552.	3.7	31
13	Mitochondrial Molecular Abnormalities Revealed by Proteomic Analysis of Hippocampal Organelles of Mice Triple Transgenic for Alzheimer Disease. Frontiers in Molecular Neuroscience, 2018, 11, 74.	2.9	30
14	Platelet biomarkers for a descending cognitive function: A proteomic approach. Aging Cell, 2021, 20, e13358.	6.7	29
15	Chronic Copper Exposure Causes Spatial Memory Impairment, Selective Loss of Hippocampal Synaptic Proteins, and Activation of PKR/eIF2Î± Pathway in Mice. Journal of Alzheimer's Disease, 2014, 43, 1413-1427.	2.6	27
16	Adiponectin alleviated Alzheimerâ€like pathologies via autophagyâ€lysosomal activation. Aging Cell, 2021, 20, e13514.	6.7	24
17	Identification of Novel Key Molecules Involved in Spatial Memory Impairment in Triple Transgenic Mice of Alzheimerâ€™s Disease. Molecular Neurobiology, 2017, 54, 3843-3858.	4.0	22
18	Proteomic Profiles of the Early Mitochondrial Changes in APP/PS1 and ApoE4 Transgenic Mice Models of Alzheimerâ€™s Disease. Journal of Proteome Research, 2019, 18, 2632-2642.	3.7	18

#	Article	IF	Citations
19	Proteomic alterations of brain subcellular organelles caused by low-dose copper exposure: implication for Alzheimerâ€™s disease. Archives of Toxicology, 2018, 92, 1363-1382.	4.2	17
20	Low-Dose Copper Exposure Exacerbates Depression-Like Behavior in ApoE4 Transgenic Mice. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-20.	4.0	17
21	Tetramethylpyrazine Improves Cognitive Impairment and Modifies the Hippocampal Proteome in Two Mouse Models of Alzheimer's Disease. Frontiers in Cell and Developmental Biology, 2021, 9, 632843.	3.7	17
22	Spatial memory impairment by TRPC1 depletion is ameliorated by environmental enrichment. Oncotarget, 2016, 7, 27855-27873.	1.8	17
23	The Isoquinoline Alkaloid Dauricine Targets Multiple Molecular Pathways to Ameliorate Alzheimer-Like Pathological Changes In Vitro. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-19.	4.0	16
24	The dualâ€functional memantine nitrate MNâ€08 alleviates cerebral vasospasm and brain injury in experimental subarachnoid haemorrhage models. British Journal of Pharmacology, 2019, 176, 3318-3335.	5.4	15
25	Dysregulation of Myosin Complex and Striated Muscle Contraction Pathway in the Brains of ALSâ€“SOD1 Model Mice. ACS Chemical Neuroscience, 2019, 10, 2408-2417.	3.5	15
26	Proteomic Profile of Mouse Brain Aging Contributions to Mitochondrial Dysfunction, DNA Oxidative Damage, Loss of Neurotrophic Factor, and Synaptic and Ribosomal Proteins. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-21.	4.0	14
27	Dauricine Attenuates Spatial Memory Impairment and Alzheimer-Like Pathologies by Enhancing Mitochondrial Function in a Mouse Model of Alzheimer's Disease. Frontiers in Cell and Developmental Biology, 2020, 8, 624339.	3.7	13
28	Platelet biomarkers identifying mild cognitive impairment in type 2 diabetes patients. Aging Cell, 2021, 20, e13469.	6.7	13
29	Hyperphosphorylation and Accumulation of Neurofilament Proteins in Transgenic Mice with Alzheimer Presenilin 1 Mutation. Cellular and Molecular Neurobiology, 2009, 29, 497-501.	3.3	12
30	SOD1 is a Possible Predictor of COVID-19 Progression as Revealed by Plasma Proteomics. ACS Omega, 2021, 6, 16826-16836.	3.5	12
31	Hippocampal Subcellular Organelle Proteomic Alteration of Copper-Treated Mice. Toxicological Sciences, 2018, 164, 250-263.	3.1	11
32	Xuesaitong Protects Podocytes from Apoptosis in Diabetic Rats through Modulating PTEN-PDK1-Akt-mTOR Pathway. Journal of Diabetes Research, 2020, 2020, 1-12.	2.3	11
33	Therapeutic efficacy of novel memantine nitrate MNâ€08 in animal models of Alzheimerâ€™s disease. Aging Cell, 2021, 20, e13371.	6.7	11
34	STAT3 ameliorates cognitive deficits by positively regulating the expression of NMDARs in a mouse model of FTDP-17. Signal Transduction and Targeted Therapy, 2020, 5, 295.	17.1	11
35	Movement deficits and neuronal loss in basal ganglia in TRPC1 deficient mice. Oncotarget, 2016, 7, 69337-69346.	1.8	10
36	Mitochondriomics reveals the underlying neuroprotective mechanism of TrkB receptor agonist R13 in the 5Ã—FAD mice. Neuropharmacology, 2022, 204, 108899.	4.1	9

#	Article	IF	Citations
37	Loganin substantially ameliorates molecular deficits, pathologies and cognitive impairment in a mouse model of Alzheimerâ€™s disease. Aging, 2021, 13, 23739-23756.	3.1	8
38	Acrolein, an endogenous aldehyde induces synaptic dysfunction in vitro and in vivo: Involvement of RhoA/ROCK2 pathway. Aging Cell, 2022, 21, e13587.	6.7	7
39	Flavanol-rich lychee fruit extract substantially reduces progressive cognitive and molecular deficits in a triple-transgenic animal model of Alzheimer disease. Nutritional Neuroscience, 2019, 24, 1-15.	3.1	5
40	Proteomic Study Reveals the Involvement of Energy Metabolism in the Fast Antidepressant Effect of (2R, 6R)â€Hydroxy Norketamine. Proteomics - Clinical Applications, 2020, 14, e1900094.	1.6	5
41	A quantitative proteomic analysis reveals the potential roles of PRDX3 in neurite outgrowth in N2a-APPswe cells. Biochemical and Biophysical Research Communications, 2022, 604, 144-150.	2.1	4
42	Manganese exposure causes movement deficit and changes in the protein profile of the external globus pallidus in Sprague Dawley rats. Toxicology and Industrial Health, 2021, 37, 715-726.	1.4	3
43	Proteomic analysis reveals the potential neuroprotective effects of tetramethylpyrazine dimer in neuro2a/APPswe cells. RSC Advances, 2019, 9, 18776-18784.	3.6	1